10.01

4.82% 0.46

After Hours: 10.01

Regenxbio Inc (RGNX)

Overview News Price History Option Chain Financials Discussions Forecast

Regenxbio Inc stock is traded at $10.01, with a volume of 627.89K. It is up +4.82% in the last 24 hours and up +7.06% over the past month. Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Previous Close:

$9.55

Open:

$9.6

24h Volume:

627.89K

Relative Volume:

1.00

Market Cap:

$496.53M

Revenue:

$89.04M

Net Income/Loss:

$-241.08M

P/E Ratio:

-1.5839

EPS:

-6.32

Net Cash Flow:

$-194.72M

1W Performance:

+3.95%

1M Performance:

+7.06%

6M Performance:

-32.91%

1Y Performance:

-47.84%

1-Day Range:

$9.39

$10.20

1-Week Range:

$9.00

$10.20

52-Week Range:

$8.535

$28.80

Regenxbio Inc Stock (RGNX) Company Profile

Name

Regenxbio Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

240-552-8181

Address

9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD

Employee

344

Twitter

@REGENXBIO

Next Earnings Date

2024-11-06

Latest SEC Filings

RGNX's Discussions on Twitter

Compare RGNX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RGNX Regenxbio Inc	10.01	496.53M	89.04M	-241.08M	-194.72M	-6.32
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Regenxbio Inc Stock (RGNX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-15-24	Resumed	Morgan Stanley	Overweight
Oct-10-24	Resumed	Raymond James	Outperform
Jun-07-24	Initiated	Goldman	Buy
Mar-11-24	Initiated	H.C. Wainwright	Buy
Mar-08-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Mar-06-24	Upgrade	Leerink Partners	Market Perform → Outperform
Feb-21-24	Resumed	Raymond James	Outperform
Nov-01-23	Initiated	Stifel	Buy
Jun-02-23	Initiated	Robert W. Baird	Outperform
Jun-23-22	Initiated	Berenberg	Buy
Dec-15-21	Initiated	Wedbush	Neutral
Oct-19-21	Resumed	Morgan Stanley	Overweight
Jan-06-21	Upgrade	Raymond James	Outperform → Strong Buy
Dec-16-20	Initiated	UBS	Buy
Jun-25-20	Resumed	BofA/Merrill	Buy
May-13-20	Initiated	RBC Capital Mkts	Sector Perform
Aug-20-19	Upgrade	SVB Leerink	Underperform → Mkt Perform
Jun-18-19	Reiterated	Chardan Capital Markets	Buy
Jun-14-19	Resumed	Raymond James	Outperform
Jun-05-19	Reiterated	Chardan Capital Markets	Buy
Feb-25-19	Upgrade	Evercore ISI	In-line → Outperform
Feb-05-19	Upgrade	Raymond James	Outperform → Strong Buy
Dec-17-18	Reiterated	Chardan Capital Markets	Buy
Nov-08-18	Reiterated	BofA/Merrill	Neutral
Aug-08-18	Reiterated	Chardan Capital Markets	Buy
Jul-23-18	Downgrade	BofA/Merrill	Buy → Neutral
Jul-10-18	Reiterated	Chardan Capital Markets	Buy
May-09-18	Reiterated	Barclays	Overweight
Apr-09-18	Reiterated	Chardan Capital Markets	Buy
Mar-12-18	Downgrade	Evercore ISI	Outperform → In-line
Feb-13-18	Initiated	Mizuho	Neutral
Nov-09-17	Resumed	Morgan Stanley	Overweight

View All

Regenxbio Inc Stock (RGNX) Latest News

Nov 26, 2024

REGENXBIO's SWOT analysis: gene therapy stock poised for growth amid challenges - Investing.com

Nov 26, 2024

Nov 25, 2024

How To Trade (RGNX) - Stock Traders Daily

Nov 25, 2024

Nov 23, 2024

Regenxbio price target lowered to $36 from $40 at H.C. Wainwright - MSN

Nov 23, 2024

Nov 21, 2024

HC Wainwright Has Lowered Expectations for REGENXBIO (NASDAQ:RGNX) Stock Price - MarketBeat

Nov 21, 2024

Regenxbio starts pivotal trial testing DMD gene therapy RGX-202 - Muscular Dystrophy News

Nov 21, 2024

Leerink Partnrs Increases Earnings Estimates for REGENXBIO - MarketBeat

Nov 21, 2024

H.C. Wainwright sees 45% approval probability for RGX-202, reiterates Buy on Regenxbio stock - Investing.com Nigeria

Nov 21, 2024

H.C. Wainwright sees 45% approval probability for RGX-202, reiterates Buy on Regenxbio stock By Investing.com - Investing.com South Africa

Nov 21, 2024

Nov 20, 2024

Chardan Capital Reaffirms Buy Rating for REGENXBIO (NASDAQ:RGNX) - MarketBeat

Nov 20, 2024

Regenxbio down 13% ahead of data readout for muscular dystrophy asset - MSN

Nov 20, 2024

Regenxbio surges 10% as it launches pivotal phase of muscular dystrophy asset trial - MSN

Nov 20, 2024

Nov 19, 2024

Regenxbio eyes 2026 filing for Duchenne muscular dystrophy gene therapy - Pharmaceutical Technology

Nov 19, 2024

US Bancorp DE Has $26,000 Stake in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World

Nov 19, 2024

Morgan Stanley Reiterates “Overweight” Rating for REGENXBIO (NASDAQ:RGNX) - Defense World

Nov 19, 2024

Raymond James maintains $18 target on RGNX after trial data - Investing.com

Nov 19, 2024

Nov 18, 2024

Regenxbio Sets Sights On 2026 Filing For DMD Gene Therapy - Citeline

Nov 18, 2024

FDA endorses speedy approval path for Regenxbio Duchenne gene therapy - BioPharma Dive

Nov 18, 2024

Raymond James maintains $18 target on RGNX after trial data By Investing.com - Investing.com UK

Nov 18, 2024

REGENXBIO (NASDAQ:RGNX) Sees Strong Trading VolumeTime to Buy? - MarketBeat

Nov 18, 2024

What's Going On With REGENXBIO Shares Monday? - Benzinga

Nov 18, 2024

Regenxbio Share Surge 20% on Duchenne Muscular Dystrophy Treatment Trial Data, Expansion - MarketWatch

Nov 18, 2024

Regenxbio (RGNX) Initiates Pivotal Phase Of Affinity Duchenne® Trial Of Rgx-202 Gene Therapy And Reports Positive Functional Data - StreetInsider.com

Nov 18, 2024

REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA - PR Newswire

Nov 18, 2024

Nov 17, 2024

REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World

Nov 17, 2024

REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Nov 17, 2024

REGENXBIO (NASDAQ:RGNX) Shares Gap Up – Should You Buy? - Defense World

Nov 17, 2024

Nov 15, 2024

Morgan Stanley bullish on Regenxbio stock, highlights gene therapy prospects By Investing.com - Investing.com South Africa

Nov 15, 2024

Morgan Stanley Reiterates "Overweight" Rating for REGENXBIO (NASDAQ:RGNX) - MarketBeat

Nov 15, 2024

Nov 14, 2024

REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202 - Kilgore News Herald

Nov 14, 2024

REGENXBIO to Present First Functional Data for Novel Duchenne Gene Therapy RGX-202 | RGNX Stock News - StockTitan

Nov 14, 2024

Nov 11, 2024

REGENXBIO FY2024 EPS Estimate Reduced by Leerink Partnrs - Defense World

Nov 11, 2024

HC Wainwright Has Positive View of REGENXBIO FY2024 Earnings - MarketBeat

Nov 11, 2024

REGENXBIO (NASDAQ:RGNX) Price Target Raised to $40.00 at HC Wainwright - Defense World

Nov 11, 2024

Analysts Offer Predictions for REGENXBIO FY2024 Earnings - MarketBeat

Nov 11, 2024

HC Wainwright Increases Earnings Estimates for REGENXBIO - Defense World

Nov 11, 2024

Nov 10, 2024

Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 10, 2024

Nov 09, 2024

Analysts Have Made A Financial Statement On REGENXBIO Inc.'s (NASDAQ:RGNX) Third-Quarter Report - Yahoo Finance

Nov 09, 2024

Nov 08, 2024

REGENXBIO Inc. (NASDAQ:RGNX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 08, 2024

REGENXBIO Third Quarter 2024 Earnings: EPS Misses Expectations - Yahoo Finance

Nov 08, 2024

Nov 07, 2024